Reinforcing transplantation with consolidation therapy in Hodgkin lymphoma
Results of Phase III POLLUX trial on daratumumab in multiple myeloma
New endpoints in clinical trials to better serve patients
Elihu H. Estey
Are we ready to use minimal residual disease (MRD) to direct multiple myeloma therapy?
Results of Phase Ib/II study of ricolinostat in multiple myeloma